Secondary metabolite profiles and antifungal drug susceptibility of Aspergillus fumigatus and closely related species, Aspergillus lentulus, Aspergillus udagawae, and Aspergillus viridinutans

Journal of Infection and Chemotherapy

Volumn 21, Issue 5, 2015, Pages 385-391

  Tamiya, Hiroyuki ^a,b   Ochiai, Eri ^a   Kikuchi, Kazuyo ^a   Yahiro, Maki ^a   Toyotome, Takahito ^a   Watanabe, Akira ^a,c   Yaguchi, Takashi ^a   Kamei, Katsuhiko ^a,c  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aspergillus fumigatus; Aspergillus lentulus; Aspergillus udagawae; Aspergillus viridinutans; Liquid chromatography time of flight mass spectrometry; Secondary metabolites

Indexed keywords

AURANTIIN; CYCLOPIAZONIC ACID; FUMAGILLIN; FUMIFUNGIN; FUMIGACLAVINE A; FUMIGACLAVINE B; FUMIGACLAVINE C; FUMIQUINAZOLINE A; FUMIQUINAZOLINE B; FUMIQUINAZOLINE D; FUMIQUINAZOLINE F; FUMIQUINAZOLINE G; FUMITREMORGIN A; FUMITREMORGIN B; FUMITREMORGIN C; GLIOTOXIN; HELVOLIC ACID; ITRACONAZOLE; METHYLSULOCHRIN; MYCOTOXIN; NEOSARTORIN; PSEUROTIN A; PSEUROTIN B; PSEUROTIN D; PYRIPYROPENE A; PYRIPYROPENE E; PYRIPYROPENE O; PYRIPYROPENE S; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS LENTULUS; ASPERGILLUS UDAGAWAE; ASPERGILLUS VIRIDINUTANS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS ISOLATION; LIQUID CHROMATOGRAPHY; METABOLITE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TIME OF FLIGHT MASS SPECTROMETRY; ASPERGILLOSIS; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; GLIOTOXIN; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; VIRULENCE FACTORS; VORICONAZOLE;

EID: 84933046921     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.01.005     Document Type: Article

References (50)

1. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999, 12:310-350.
2. Balajee S.A., Gribskov J.L., Hanley E., Nickle D., Marr K.A. Aspergillus lentulus sp. nov., a new sibling species of A.fumigatus. Eukaryot Cell 2005, 4:625-632.
3. Balajee S.A., Nickle D., Varga J., Marr K.A. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell 2006, 5:1705-1712.
4. Samson R.A., Hong S., Peterson S.W., Frisvad J.C., Varga J. Polyphasic taxonomy of Aspergillus section Fumigati and its teleomorph Neosartorya. Stud Mycol 2007, 59:147-203.
5. Vinh D.C., Shea Y.R., Jones P.A., Freeman A.F., Zelazny A., Holland S.M. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009, 15:1292-1294.
6. Coelho D., Silva S., Vale-Silva L., Gomes H., Pinto E., Sarmento A., et al. Aspergillus viridinutans: an agent of adult chronic invasive aspergillosis. Med Mycol 2011, 49:755-759.
7. Hong S.B., Kim D.H., Park I.C., Choi Y.J., Shin H.D., Samson R. Re-identification of Aspergillus fumigatus sensu lato based on a new concept of species delimitation. JMicrobiol 2010, 48:607-615.
8. Vinh D.C., Shea Y.R., Sugui J.A., Parrilla-Castellar E.R., Freeman A.F., Campbell J.W., et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009, 49:102-111.
9. Alhambra A., Catalan M., Moragues M.D., Brena S., Ponton J., Montejo J.C., et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol 2008, 25:246-249.
10. Etzel R.A. Mycotoxins. JAMA 2002, 287:425-427.
11. Kamei K., Watanabe A. Aspergillus mycotoxins and their effect on the host. Med Mycol 2005, 43:S95-S99.
12. Watanabe A., Kamei K., Sekine T., Higurashi H., Ochiai E., Hashimoto Y., et al. Cytotoxic substances from Aspergillus fumigatus in oxygenated or poorly oxygenated environment. Mycopathologia 2004, 158:1-7.
13. Stanzani M., Orciuolo E., Lewis R., Kontoyiannis D.P., Martins S.L., St John L.S., et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 2005, 105:2258-2265.
14. Sugui J.A., Pardo J., Chang Y.C., Zarember K.A., Nardone G., Galvez E.M., et al. Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell 2007, 6:1562-1569.
15. Lewis R.E., Wiederhold N.P., Lionakis M.S., Prince R.A., Kontoyiannis D.P. Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. JClin Microbiol 2005, 43:6120-6122.
16. Frisvad J.C., Rank C., Nielsen K.F., Larsen T.O. Metabolomics of Aspergillus fumigatus. Med Mycol 2009, 47:S53-S71.
17. Sugui J.A., Vinh D.C., Nardone G., Shea Y.R., Chang Y.C., Zelazny A.M., et al. Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus?. JClin Microbiol 2010, 48:220-228.
18. Larsen T.O., Smedsgaard J., Nielsen K.F., Hansen M.A., Samson R.A., Frisvad J.C. Production of mycotoxins by Aspergillus lentulus and other medically important and closely related species in section Fumigati. Med Mycol 2007, 45:225-232.
19. Yaguchi T., Horie Y., Tanaka R., Matsuzawa T., Ito J., Nishimura K. Molecular phylogenetics of multiple genes on Aspergillus section Fumigati isolated from clinical specimens in Japan. Nihon Ishinkin Gakkai Zasshi 2007, 48:37-46.
20. Watanabe A., Kamei K., Sekine T., Waku M., Nishimura K., Miyaji M., et al. Immunosuppressive substances in Aspergillus fumigatus culture filtrate. JInfect Chemother 2003, 9:114-121.
21. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing for filamentous fungi; approved standard 2008, Document M38-A2, Clinical and Laboratory Standards Institute, Wayne, PA.
22. Espinel-Ingroff A., Diekema D.J., Fothergill A., Johnson E., Pelaez T., Pfaller M.A., et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). JClin Microbiol 2010, 48:3251-3257.
23. Espinel-Ingroff A., Cuenca-Estrella M., Fothergill A., Fuller J., Ghannoum M., Johnson E., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011, 55:5150-5154.
24. Hong S.B., Go S.J., Shin H.D., Frisvad J.C., Samson R.A. Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia 2005, 97:1316-1329.
25. Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Cuenca-Estrella M., Rodriguez-Tudela J.L. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008, 52:1244-1251.
26. Balajee S.A., Weaver M., Imhof A., Gribskov J., Marr K.A. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004, 48:1197-1203.
27. Gyotoku H., Izumikawa K., Ikeda H., Takazono T., Morinaga Y., Nakamura S., et al. Acase of bronchial aspergillosis caused by Aspergillus udagawae and its mycological features. Med Mycol 2012, 50:631-636.
28. Ben-Ami R., Lewis R.E., Leventakos K., Kontoyiannis D.P. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009, 114:5393-5399.
29. Amitani R., Taylor G., Elezis E.N., Llewellyn-Jones C., Mitchell J., Kuze F., et al. Purification and characterization of factors produced by Aspergillus fumigatus which affect human ciliated respiratory epithelium. Infect Immun 1995, 63:3266-3271.
30. Comera C., Andre K., Laffitte J., Collet X., Galtier P., Maridonneau-Parini I. Gliotoxin from Aspergillus fumigatus affects phagocytosis and the organization of the actin cytoskeleton by distinct signalling pathways in human neutrophils. Microbes Infect 2007, 9:47-54.
31. Tsunawaki S., Yoshida L.S., Nishida S., Kobayashi T., Shimoyama T. Fungal metabolite gliotoxin inhibits assembly of the human respiratory burst NADPH oxidase. Infect Immun 2004, 72:3373-3382.
32. Khoufache K., Puel O., Loiseau N., Delaforge M., Rivollet D., Coste A., et al. Verruculogen associated with Aspergillus fumigatus hyphae and conidia modifies the electrophysiological properties of human nasal epithelial cells. BMC Microbiol 2007, 23:5.
33. Fallon J.P., Reeves E.P., Kavanagh K. Inhibition of neutrophil function following exposure to the Aspergillus fumigatus toxin fumagillin. JMed Microbiol 2010, 59:625-633.
34. Fallon J.P., Reeves E.P., Kavanagh K. The Aspergillus fumigatus toxin fumagillin suppresses the immune response of Galleria mellonella larvae by inhibiting the action of haemocytes. Microbiology 2011, 157:1481-1488.
35. Tomee J.F., Kauffman H.F. Putative virulence factors of Aspergillus fumigatus. Clin Exp Allergy 2000, 30:476-484.
36. Coleman J.J., Ghosh S., Okoli I., Mylonakis E. Antifungal activity of microbial secondary metabolites. PLoS One 2011, 6:e25321.
37. Schmeda-Hirschmann G., Hormazabal E., Rodriguez J.A., Theoduloz C. Cycloaspeptide A and pseurotin A from the endophytic fungus Penicillium janczewskii. ZNaturforsch C 2008, 63:383-388.
38. Ishikawa M., Ninomiya T., Akabane H., Kushida N., Tsujiuchi G., Ohyama M., et al. Pseurotin A and its analogues as inhibitors of immunoglobulin E [correction of immunoglobuline E] production. Bioorg Med Chem Lett 2009, 19:1457-1460.
39. Vodisch M., Scherlach K., Winkler R., Hertweck C., Braun H.P., Roth M., et al. Analysis of the Aspergillus fumigatus proteome reveals metabolic changes and the activation of the pseurotin A biosynthesis gene cluster in response to hypoxia. JProteome Res 2011, 10:2508-2524.
40. Ohashi H., Ishikawa M., Ito J., Ueno A., Gleich G.J., Kita H., et al. Sulochrin inhibits eosinophil degranulation. JAntibiot - Tokyo 1997, 50:972-974.
41. Ohashi H., Motegi Y., Kita H., Gleich G.J., Miura T., Ishikawa M., et al. Sulochrin inhibits eosinophil activation and chemotaxis. Inflamm Res 1998, 47:409-415.
42. Lee H.J., Lee J.H., Hwang B.Y., Kim H.S., Lee J.J. Fungal metabolites, asterric acid derivatives inhibit vascular endothelial growth factor (VEGF)-induced tube formation of HUVECs. JAntibiot - Tokyo 2002, 55:552-556.
43. Takahashi C., Matsushita T., Doi M., Minoura K., Shingu T. Fumiquinazolines A-G, novel metabolites of a fungus separated from a Pseudolabrus marine fish. JChem Soc Perkin Trans I 1995, 18:2345-2353.
44. Coyle C.M., Kenaley S.C., Rittenour W.R., Panaccione D.G. Association of ergot alkaloids with conidiation in Aspergillus fumigatus. Mycologia 2007, 99:804-811.
45. Cole R.J., Cox R.H. Tremorgin group. Handbook of toxic fungal metabolites 1981, 355-509. Academic Press, New York. R.J. Cole (Ed.).
46. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, 60:47-50.
47. Balan J., Ebringer L., Nemec P., Kovac S., Dobias J. Antiprotozoal Antibiotics. II. Isolation and characterization of trypacidin, a new antibiotic, active against Trypanosoma cruzi and Toxoplasma gondii. JAntibiot - Tokyo 1963, 16:157-160.
48. Hayashi A., Arai M., Fujita M., Kobayashi M. Pyripyropenes, fungal sesquiterpenes conjugated with alpha-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells. Biol Pharm Bull 2009, 32:1261-1265.
49. Mellado E., Alcazar-Fuoli L., Cuenca-Estrella M., Rodriguez-Tudela J.L. Role of Aspergillus lentulus 14-alpha sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother 2011, 55:5459-5468.
50. Masia Canuto M., Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002, 2:550-563.